VAPORIZING DEVICE

Description

The present industrial model consists of the vaporizing device. It comprises a body and a removable cartridge. The shapes of the body and the cartridge are such that, WHEN THE CARTRIDGE IS CONNECTED TO THE BODY, THE VAPORIZING DEVICE HAS AN APPEARANCE OF A SINGLE ELEMENT. THE MODEL IS CHARACTERIZED BY ITS BLACK APPEARANCE. THE MODEL IN GENERAL It has a basic shape derived from a rectangular prism. From that shape BASIC, THE RECTANGULAR BASES OF THE VAPORIZING DEVICE HAVE SHORT SIDES AND LONG SIDES Long, curved, convex from the outside. This shape of the bases is maintained along the length of the LENGTH OF THE DEVICE, SHAPED BY THE SHORT SIDES, THE EDGES OF THE DEVICE, AND THE LONG SIDES THE FRONT AND BACK OF THE DEVICE. ACCORDING TO THE SHAPE OF THE BASES, THE SHAPE OF THE The cross-section of the vaporizing device is tapered. “The vaporizing device rests on ONE OF THE BASES DESCRIBED ABOVE. ON THE OPPOSITE BASE, THE BODY COMPRISES A CAVITY Configured to receive a removable cartridge insert portion. The removable cartridge IT HAS AN EXTERNAL PORTION CONFIGURED IN SUCH A WAY THAT THE EXTERNAL SHAPES OF THE BODY AND OF The cartridge provides continuity to the device's outline. Viewing the vaporizer device FROM ITS EDGES, THE REMOVABLE CARTRIDGE HAS THE SAME WIDTH AS THE BODY IN THE CONNECTION AREA AND A LESSER WIDTH AT THE END OF THE CARTRIDGE, FORMING A NARROWING AT THE END OF THE DEVICE CORRESPONDING TO THE CARTRIDGE. THE RELATIONSHIP BETWEEN THE DIMENSIONS OF THE DEVICE THEY GIVE A SLENDER APPEARANCE. 88 X EP 1 438 973 A1 (ONO PHARMACEUTICAL CO [JP] 21 DE JULIO DE 2004 (2004-07-21) VÉANSE EXAMPLES 1 (5) AND 1 (79) Claims affected 18.19 X WO 2011 / 157688 A1 (BAYER PHARMA AG [DE]; SCHULZE VOLKER [DE], 22 DECEMBER 2011 (2011-12-22) SEE PREFERRED EMBODIMENT ON PAGE 32, 1. 19 TO 25, INTERMEDIARIES OF FORMULA (4) ON PAGE 73, THEIR USE ON PAGE 75, THE METHOD COMPRISING SAID INTERMEDIARIES ON PAGE 71, GRAPH 1 ON PAGE 80, THE PASSAGE ON PAGE 83, 1.2 TO 10, THE ACIDS BORONICS USED FOR INT03.1, INT03.04, INT.04.01, INT05.01, INT06.01, AND INT07.01 AND CLAIM 17. Claims affected 1-20 WO 2011 / 06432 A1 JUNE 3, 2011 (2011-06-03) MENTIONED IN THE APPLICATION SEE GRAPH 1 ON PAGE 51, THE PASSAGE IN PAGE 53, 1. 18 TO 25, INTERMEDIARY 3.1 AND EXAMPLES 3.10 AND 11.009 Claims affected 14-20 AND WO 2011 / 06432 A1 (BAYER SCHERING PHARMA AG [DE]; KOPPITZ MARCUS [DE]; SCHULZE VOLKER [DE]) JUNE 3, 2011 (2011-06-03) MENTIONED IN THE APPLICATION SEE GRAPH 1 ON PAGE 51, THE PASSAGE IN PAGE 53, 1. 18 TO 25, INTERMEDIARY 3.1 AND EXAMPLES 3.10 AND 11.009 Claims affected 1-20 X WO 2011 / 063908 A1 (BAYER SCHERING PHARMA AG [DE], JUNE 3, 2011 (2011-06-03) MENTIONED IN THE APPLICATION SEE GRAPH I ON PAGE 41, AND PAGE 43, 1.22 A 29, INTERMEDIARY 3.1 AND EXAMPLE 2.1 Claims affected 14,20 AND SEE GRAPH 1 ON PAGE 41, AND PAGE 43, 1. 22 TO 29, INTERMEDIARY 3.1 AND EXAMPLE 2.1 Claims affected 1-20 X,P WO 2012 / 160029 A1 (BAYER IP GMBH [DE], SCHULZE VOLKER [DE], KOSEMUND DIRK [DE], A) NOVEMBER 29, 2012 (2012-11-29) SEE DEFINITION OF R1 AND R2 ON PAGE 43, THE PREPARATION IN PAGE 51 INCLUDING THE FORMULA INTERMEDIARY (4), SAID INTERMEDIARY ON PAGE 53, GRAPH I IN Page 59 and Page 62, 1.3 to 10, Boronic acid derivative for the preparation of intermediate 3.1 and CLAIM 11. Claims affected 1-20 X JARED H DELCAMP ET AL: "A GENERAL AND HIGHLY SELECTIVE CHELATE-CONTROLLED INTERMOLECULAR OXIDATIVE HECK REATION", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, ACS PUBLICATIONS, US VOLUME 13, N°34, AUGUST 27, 2008 (2008-08-27), PAGES. 11270-11271, XP009172460 ISSN: 0002-7863, DOI: 10. 1021 / JA804120R SEE PHENYLBORONIC ACID STARTING MATERIAL FOR COMPOUNDS 1 AND 2 IN TABLE 1. Claims affected 14 WO 2005 / 110410 A2 [US];) 24 NOVEMBER 2005 (2005-11-24) SEE BORONATE OF THE LAST COMPOUND ON PAGE 224 AND PREPARATION 163 Claims affected 14 Observations: THIS REPORT WAS BASED ON THE PCT INTERNATIONAL SEARCH REPORT OF THE OFFICE EUROPEAN PATENT REGISTRATION NO. WO 2014 / 009219 Date of report completion: December 12, 2017